{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T19:28:01Z","timestamp":1680031681113},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00115-019-0761-z","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T13:03:04Z","timestamp":1562590984000},"page":"809-816","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gentherapien f\u00fcr neuromuskul\u00e4re Erkrankungen"],"prefix":"10.1007","volume":"90","author":[{"given":"Afshin","family":"Saffari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Weiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg Friedrich","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"761_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14712598.2018.1479739","volume":"18","author":"S Aguti","year":"2018","unstructured":"Aguti\u00a0S, Malerba\u00a0A, Zhou\u00a0H (2018) The progress of AAV-mediated gene therapy in neuromuscular disorders. Expert Opin Biol Ther 18:681\u2013693","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 1","key":"761_CR2","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1038\/sj.gt.3302379","volume":"11","author":"T Athanasopoulos","year":"2004","unstructured":"Athanasopoulos\u00a0T, Graham\u00a0IR, Foster\u00a0H et al (2004) Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther 11(Suppl 1):S109\u2013S121","journal-title":"Gene Ther"},{"key":"761_CR3","doi-asserted-by":"publisher","first-page":"R42","DOI":"10.1093\/hmg\/ddr142","volume":"20","author":"A Biffi","year":"2011","unstructured":"Biffi\u00a0A, Aubourg\u00a0P, Cartier\u00a0N (2011) Gene therapy for leukodystrophies. Hum Mol Genet 20:R42\u2013R53","journal-title":"Hum Mol Genet"},{"key":"761_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby\u00a0K, Finkel\u00a0R, Wong\u00a0B et\u00a0al (2014) Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50:477\u2013487","journal-title":"Muscle Nerve"},{"key":"761_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/mt.2013.246","volume":"22","author":"LG Chicoine","year":"2014","unstructured":"Chicoine\u00a0LG, Rodino-Klapac\u00a0LR, Shao\u00a0G et al (2014) Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin alpha2 surrogates. Mol Ther 22:713\u2013724","journal-title":"Mol Ther"},{"key":"761_CR6","doi-asserted-by":"publisher","first-page":"44775","DOI":"10.1038\/srep44775","volume":"7","author":"JR Counsell","year":"2017","unstructured":"Counsell\u00a0JR, Asgarian\u00a0Z, Meng\u00a0J et al (2017) Lentiviral vectors can be used for full-length dystrophin gene therapy. Sci Rep 7:44775","journal-title":"Sci Rep"},{"key":"761_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1126\/science.1142658","volume":"317","author":"A Donsante","year":"2007","unstructured":"Donsante\u00a0A, Miller\u00a0DG, Li\u00a0Y et\u00a0al (2007) AAV vector integration sites in mouse hepatocellular carcinoma. Science 317:477","journal-title":"Science"},{"key":"761_CR8","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","volume":"72","author":"D Duan","year":"1998","unstructured":"Duan\u00a0D, Sharma\u00a0P, Yang\u00a0J et al (1998) Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J\u00a0Virol 72:8568\u20138577","journal-title":"J Virol"},{"key":"761_CR9","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel\u00a0RS, Mercuri\u00a0E, Darras\u00a0BT et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N\u00a0Engl J Med 377:1723\u20131732","journal-title":"N Engl J Med"},{"key":"761_CR10","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/mt.2016.52","volume":"24","author":"I Gil-Farina","year":"2016","unstructured":"Gil-Farina\u00a0I, Fronza\u00a0R, Kaeppel\u00a0C et al (2016) Recombinant AAV integration is not associated with hepatic Genotoxicity in nonhuman primates and patients. Mol Ther 24:1100\u20131105","journal-title":"Mol Ther"},{"key":"761_CR11","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/mt.2010.106","volume":"18","author":"P Hadaczek","year":"2010","unstructured":"Hadaczek\u00a0P, Eberling\u00a0JL, Pivirotto\u00a0P et al (2010) Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 18:1458\u20131461","journal-title":"Mol Ther"},{"key":"761_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer\u00a0C, Katz\u00a0N, Buza\u00a0EL et al (2018) Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther 29:285\u2013298","journal-title":"Hum Gene Ther"},{"key":"761_CR13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nbt0702-735","volume":"20","author":"R Hirata","year":"2002","unstructured":"Hirata\u00a0R, Chamberlain\u00a0J, Dong\u00a0R et al (2002) Targeted transgene insertion into human chromosomes by adeno-associated virus vectors. Nat Biotechnol 20:735\u2013738","journal-title":"Nat Biotechnol"},{"key":"761_CR14","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","volume":"372","author":"SG Jacobson","year":"2015","unstructured":"Jacobson\u00a0SG, Cideciyan\u00a0AV, Roman\u00a0AJ et\u00a0al (2015) Improvement and decline in vision with gene therapy in childhood blindness. N\u00a0Engl J Med 372:1920\u20131926","journal-title":"N Engl J Med"},{"key":"761_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/hum.2017.095","volume":"29","author":"K Kodippili","year":"2018","unstructured":"Kodippili\u00a0K, Hakim\u00a0CH, Pan\u00a0X et al (2018) Dual AAV gene therapy for Duchenne muscular dystrophy with a\u00a07-kb mini-Dystrophin gene in the canine model. Hum Gene Ther 29:299\u2013311","journal-title":"Hum Gene Ther"},{"key":"761_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/hgtb.2012.243","volume":"24","author":"LV Jeune","year":"2013","unstructured":"Jeune\u00a0LV, Joergensen\u00a0JA, Hajjar\u00a0RJ et al (2013) Pre-existing anti-adeno-associated virus antibodies as a\u00a0challenge in AAV gene therapy. Hum Gene Ther Methods 24:59\u201367","journal-title":"Hum Gene Ther Methods"},{"key":"761_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","volume":"38","author":"DM Mccarty","year":"2004","unstructured":"Mccarty\u00a0DM, Young\u00a0SM Jr., Samulski\u00a0RJ (2004) Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38:819\u2013845","journal-title":"Annu Rev Genet"},{"key":"761_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell\u00a0JR, Al-Zaidy\u00a0S, Shell\u00a0R et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N\u00a0Engl J Med 377:1713\u20131722","journal-title":"N Engl J Med"},{"key":"761_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell\u00a0JR, Goemans\u00a0N, Lowes\u00a0LP et\u00a0al (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79:257\u2013271","journal-title":"Ann Neurol"},{"key":"761_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/ana.22251","volume":"68","author":"JR Mendell","year":"2010","unstructured":"Mendell\u00a0JR, Rodino-Klapac\u00a0LR, Rosales\u00a0XQ et al (2010) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68:629\u2013638","journal-title":"Ann Neurol"},{"key":"761_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/mt.2014.200","volume":"23","author":"JR Mendell","year":"2015","unstructured":"Mendell\u00a0JR, Sahenk\u00a0Z, Malik\u00a0V et\u00a0al (2015) A phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther 23:192\u2013201","journal-title":"Mol Ther"},{"key":"761_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2014.210","volume":"23","author":"K Meyer","year":"2015","unstructured":"Meyer\u00a0K, Ferraiuolo\u00a0L, Schmelzer\u00a0L et al (2015) Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a\u00a0dose-response study in mice and nonhuman primates. Mol Ther 23:477\u2013487","journal-title":"Mol Ther"},{"key":"761_CR23","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani\u00a0AC, Reiss\u00a0UM, Tuddenham\u00a0EG et al (2014) Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N\u00a0Engl J Med 371:1994\u20132004","journal-title":"N Engl J Med"},{"key":"761_CR24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ng.3389","volume":"47","author":"JC Nault","year":"2015","unstructured":"Nault\u00a0JC, Datta\u00a0S, Imbeaud\u00a0S et al (2015) Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 47:1187\u20131193","journal-title":"Nat Genet"},{"key":"761_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson\u00a0CE, Hakim\u00a0CH, Ousterout\u00a0DG et\u00a0al (2016) In vivo genome editing improves muscle function in a\u00a0mouse model of Duchenne muscular dystrophy. Science 351:403\u2013407","journal-title":"Science"},{"key":"761_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JND-180315","volume":"5","author":"A Pechmann","year":"2018","unstructured":"Pechmann\u00a0A, Langer\u00a0T, Schorling\u00a0D et\u00a0al (2018) Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany. J\u00a0Neuromuscul Dis 5:135\u2013143","journal-title":"J Neuromuscul Dis"},{"key":"761_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/sj.gt.3303037","volume":"15","author":"H Petry","year":"2008","unstructured":"Petry\u00a0H, Brooks\u00a0A, Orme\u00a0A et al (2008) Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther 15:54\u201360","journal-title":"Gene Ther"},{"key":"761_CR28","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1038\/mt.2012.197","volume":"20","author":"LE Rosas","year":"2012","unstructured":"Rosas\u00a0LE, Grieves\u00a0JL, Zaraspe\u00a0K et\u00a0al (2012) Patterns of scAAV vector insertion associated with oncogenic events in a\u00a0mouse model for genotoxicity. Mol Ther 20:2098\u20132110","journal-title":"Mol Ther"},{"key":"761_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/mt.2013.250","volume":"22","author":"Z Sahenk","year":"2014","unstructured":"Sahenk\u00a0Z, Galloway\u00a0G, Clark\u00a0KR et al (2014) AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy. Mol Ther 22:511\u2013521","journal-title":"Mol Ther"},{"key":"761_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/sj.mt.6300027","volume":"15","author":"MZ Salva","year":"2007","unstructured":"Salva\u00a0MZ, Himeda\u00a0CL, Tai\u00a0PW et al (2007) Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther 15:320\u2013329","journal-title":"Mol Ther"},{"key":"761_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","volume":"16","author":"V Sudhakar","year":"2019","unstructured":"Sudhakar\u00a0V, Richardson\u00a0RM (2019) Gene therapy for neurodegenerative diseases. Neurotherapeutics 16:166\u2013175","journal-title":"Neurotherapeutics"},{"issue":"5","key":"761_CR32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang\u00a0D, Tai\u00a0PWL, Gao\u00a0G (2019) Adeno-associated virus vector as a\u00a0platform for gene therapy delivery. Nat Rev Drug Discov 18(5):358\u2013378. \n                    https:\/\/doi.org\/10.1038\/s41573-019-0012-9","journal-title":"Nat Rev Drug Discov"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-0761-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-019-0761-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-0761-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T23:05:48Z","timestamp":1594076748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-019-0761-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1007\/s00115-019-0761-z","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,8]]},"assertion":[{"value":"8 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Saffari hat an wissenschaftlichen Veranstaltungen teilgenommen, die von den Firmen Biogen und Sarepta Therapeutics gesponsort wurden. Diese Firmen stellen Therapien f\u00fcr neuromuskul\u00e4re Erkrankungen her. M.\u00a0Weiler hat an wissenschaftlichen Veranstaltungen teilgenommen, die von den Firmen Biogen und Pfizer gesponsort wurden. Er ist als Berater f\u00fcr Advisory Boards sowie als Referent f\u00fcr Fortbildungsveranstaltungen und Industriesymposien der Firmen Akcea Therapeutics und Biogen t\u00e4tig. Diese Firmen stellen Therapien f\u00fcr neuromuskul\u00e4re Erkrankungen her. A.\u00a0Ziegler hat an wissenschaftlichen Veranstaltungen teilgenommen, die von den Firmen Biogen und Sarepta Therapeutics gesponsort wurden. Er ist als Berater f\u00fcr Advisory Boards der Firmen PTC, Avexis, Biogen und Roche t\u00e4tig. Zudem ist er als Referent f\u00fcr Industriesymposien der Firmen Biogen und Avexis eingeladen. Diese Firmen stellen Therapien f\u00fcr neuromuskul\u00e4re Erkrankungen her. G.F.\u00a0Hoffmann gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}